Altre lingue Seelos Therapeutics, Inc.

Azioni

SEEL

US81577F3073

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 10/07/2024			Variaz. 5gg	Var. 1 gen.
0,7265 ^USD	+6,84%		+28,58%	-93,47%

14/05	Seelos Therapeutics attuerà un frazionamento azionario inverso per riguadagnare la conformità al Nasdaq	MT
14/05	Seelos Therapeutics, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	17/05
Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	16/05
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	14/05
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split	14/05
Seelos: Q1 Earnings Snapshot	14/05
Seelos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Seelos Therapeutics, Inc. Announces Resignation of Daniel J. O?Connor from the Board	03/05
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations	29/04
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	29/04
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	19/03
Seelos Therapeutics' ALS treatment fails in mid-stage study	19/03
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)	19/03
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	19/03
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	04/03
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	04/03
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	29/01
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	26/01
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	26/01
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration	23/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Seelos Therapeutics, Inc.

Azioni

SEEL

US81577F3073

Altre lingue

Filtri